SI20875A - Kristalna oblika omeprazola - Google Patents

Kristalna oblika omeprazola Download PDF

Info

Publication number
SI20875A
SI20875A SI200100111A SI200100111A SI20875A SI 20875 A SI20875 A SI 20875A SI 200100111 A SI200100111 A SI 200100111A SI 200100111 A SI200100111 A SI 200100111A SI 20875 A SI20875 A SI 20875A
Authority
SI
Slovenia
Prior art keywords
omeprazole
weak
medium
strong
preparation
Prior art date
Application number
SI200100111A
Other languages
English (en)
Slovenian (sl)
Inventor
MILA� Nata�a HAFNER
Anton Opar
Barbara Podobnik
Bel�i� Andreja Cizerle
Alenka Ko�ak
Brina Ornik
Uro� Urleb
Original Assignee
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20432882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI20875(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. filed Critical LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.
Priority to SI200100111A priority Critical patent/SI20875A/sl
Priority to RU2003133213/04A priority patent/RU2286991C2/ru
Priority to MXPA03009789A priority patent/MXPA03009789A/es
Priority to US10/475,239 priority patent/US20040122056A1/en
Priority to NZ528917A priority patent/NZ528917A/en
Priority to JP2002583416A priority patent/JP4455815B2/ja
Priority to DE60216273T priority patent/DE60216273T2/de
Priority to UA2003109492A priority patent/UA77671C2/uk
Priority to CA2445251A priority patent/CA2445251C/en
Priority to EP02764081A priority patent/EP1390360B1/en
Priority to PCT/IB2002/001350 priority patent/WO2002085889A1/en
Priority to PL02366471A priority patent/PL366471A1/xx
Priority to BR0209103-8A priority patent/BR0209103A/pt
Priority to CZ20032911A priority patent/CZ20032911A3/cs
Priority to AT02764081T priority patent/ATE346063T1/de
Priority to SK1319-2003A priority patent/SK13192003A3/sk
Priority to KR10-2003-7013767A priority patent/KR20030094358A/ko
Priority to CN028089553A priority patent/CN1531533B/zh
Priority to HU0303928A priority patent/HUP0303928A2/hu
Priority to YUP-840/03A priority patent/RS50880B/sr
Priority to IL15856102A priority patent/IL158561A0/xx
Priority to SI200230491T priority patent/SI1390360T1/sl
Priority to AU2002307892A priority patent/AU2002307892B2/en
Publication of SI20875A publication Critical patent/SI20875A/sl
Priority to ZA200307988A priority patent/ZA200307988B/xx
Priority to HR20030853A priority patent/HRP20030853B1/xx
Priority to NO20034715A priority patent/NO20034715L/no
Priority to BG108287A priority patent/BG108287A/bg
Priority to US11/248,461 priority patent/US7553856B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SI200100111A 2001-04-25 2001-04-25 Kristalna oblika omeprazola SI20875A (sl)

Priority Applications (28)

Application Number Priority Date Filing Date Title
SI200100111A SI20875A (sl) 2001-04-25 2001-04-25 Kristalna oblika omeprazola
AU2002307892A AU2002307892B2 (en) 2001-04-25 2002-04-24 Crystalline form of omeprazole
BR0209103-8A BR0209103A (pt) 2001-04-25 2002-04-24 Omeprazol forma c, processo para preparação e uso do mesmo e formulação farmacêutica
AT02764081T ATE346063T1 (de) 2001-04-25 2002-04-24 Kristalline form von omeprazol
US10/475,239 US20040122056A1 (en) 2001-04-25 2002-04-24 Crystalline form of omeprazole
NZ528917A NZ528917A (en) 2001-04-25 2002-04-24 Crystalline form of omeprazole
JP2002583416A JP4455815B2 (ja) 2001-04-25 2002-04-24 オメプラゾールのｃ型結晶の製造方法
DE60216273T DE60216273T2 (de) 2001-04-25 2002-04-24 Kristalline form von omeprazol
UA2003109492A UA77671C2 (en) 2001-04-25 2002-04-24 Crystalline form of omeprazole
CA2445251A CA2445251C (en) 2001-04-25 2002-04-24 Crystalline form of omeprazole
EP02764081A EP1390360B1 (en) 2001-04-25 2002-04-24 Crystalline form of omeprazole
PCT/IB2002/001350 WO2002085889A1 (en) 2001-04-25 2002-04-24 Crystalline form of omeprazole
PL02366471A PL366471A1 (en) 2001-04-25 2002-04-24 Crystalline form of omeprazole
RU2003133213/04A RU2286991C2 (ru) 2001-04-25 2002-04-24 Форма омепразола, способ его получения и его применение
CZ20032911A CZ20032911A3 (en) 2001-04-25 2002-04-24 Crystalline form of omeprazole
MXPA03009789A MXPA03009789A (es) 2001-04-25 2002-04-24 Forma cristalina de omeprazol.
SK1319-2003A SK13192003A3 (sk) 2001-04-25 2002-04-24 Kryštalická forma omeprazolu
KR10-2003-7013767A KR20030094358A (ko) 2001-04-25 2002-04-24 결정형의 오미프라졸
CN028089553A CN1531533B (zh) 2001-04-25 2002-04-24 奥美拉唑的晶形
HU0303928A HUP0303928A2 (hu) 2001-04-25 2002-04-24 Omeprazol kristályos formája, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
YUP-840/03A RS50880B (sr) 2001-04-25 2002-04-24 Kristalna forma omeprazola
IL15856102A IL158561A0 (en) 2001-04-25 2002-04-24 Crystalline form of omerprazole
SI200230491T SI1390360T1 (sl) 2001-04-25 2002-04-24 Kristalna oblika omeprazola
ZA200307988A ZA200307988B (en) 2001-04-25 2003-10-14 Crystalline form of omerprazole.
HR20030853A HRP20030853B1 (en) 2001-04-25 2003-10-20 Crystalline form of omeprazole
NO20034715A NO20034715L (no) 2001-04-25 2003-10-21 Krystallinsk form av omeprazol
BG108287A BG108287A (bg) 2001-04-25 2003-10-24 Кристална форма на омепразол
US11/248,461 US7553856B2 (en) 2001-04-25 2005-10-12 Crystalline form of omeprazole

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI200100111A SI20875A (sl) 2001-04-25 2001-04-25 Kristalna oblika omeprazola

Publications (1)

Publication Number Publication Date
SI20875A true SI20875A (sl) 2002-10-31

Family

ID=20432882

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200100111A SI20875A (sl) 2001-04-25 2001-04-25 Kristalna oblika omeprazola
SI200230491T SI1390360T1 (sl) 2001-04-25 2002-04-24 Kristalna oblika omeprazola

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200230491T SI1390360T1 (sl) 2001-04-25 2002-04-24 Kristalna oblika omeprazola

Country Status (26)

Country Link
US (2) US20040122056A1 (hu)
EP (1) EP1390360B1 (hu)
JP (1) JP4455815B2 (hu)
KR (1) KR20030094358A (hu)
CN (1) CN1531533B (hu)
AT (1) ATE346063T1 (hu)
AU (1) AU2002307892B2 (hu)
BG (1) BG108287A (hu)
BR (1) BR0209103A (hu)
CA (1) CA2445251C (hu)
CZ (1) CZ20032911A3 (hu)
DE (1) DE60216273T2 (hu)
HR (1) HRP20030853B1 (hu)
HU (1) HUP0303928A2 (hu)
IL (1) IL158561A0 (hu)
MX (1) MXPA03009789A (hu)
NO (1) NO20034715L (hu)
NZ (1) NZ528917A (hu)
PL (1) PL366471A1 (hu)
RS (1) RS50880B (hu)
RU (1) RU2286991C2 (hu)
SI (2) SI20875A (hu)
SK (1) SK13192003A3 (hu)
UA (1) UA77671C2 (hu)
WO (1) WO2002085889A1 (hu)
ZA (1) ZA200307988B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
EP1904064A4 (en) * 2005-07-07 2009-12-02 Reddys Lab Ltd Dr OMEPRAZOLE OF FORM B
PL1988163T3 (pl) * 2006-02-22 2012-11-30 Int Inst Cancer Immunology Inc Ograniczony do hla-a*3303 peptyd wt1 i zawierająca go kompozycja farmaceutyczna
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2486910A3 (en) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Multi-chambered apparatus comprising a dispenser head
EP2114919A2 (en) 2007-01-31 2009-11-11 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic seperation
WO2010134099A1 (en) 2009-05-21 2010-11-25 Cadila Healthcare Limited One pot process for preparing omeprazole and related compounds
CN102786513A (zh) * 2011-05-18 2012-11-21 中国医学科学院药物研究所 奥美拉唑晶e型物质及制备方法与在药品和保健品中应用
CN102351846B (zh) * 2011-09-07 2012-08-22 周晓东 一种新的奥美拉唑钠化合物及其药物组合物
KR101459088B1 (ko) * 2012-08-02 2014-12-02 대화제약 주식회사 알-라베프라졸, 이의 금속염의 제조방법
EP4426694A1 (en) * 2021-11-05 2024-09-11 Cinclus Pharma Holding AB (publ) Polymorphs of the hydrochloride salt of linaprazan glurate
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
ES2078447T3 (es) * 1990-06-15 1995-12-16 Merck & Co Inc Un procedimiento de cristalizacion para mejorar la estructura y el tamaño de los cristales.
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SI20019A (sl) * 1998-07-13 2000-02-29 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
US6166213A (en) * 1998-08-11 2000-12-26 Merck & Co., Inc. Omeprazole process and compositions thereof
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
AUPQ841800A0 (en) * 2000-06-28 2000-07-20 Biomolecular Research Institute Limited Truncated egf receptor
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs

Also Published As

Publication number Publication date
YU84003A (sh) 2006-08-17
EP1390360B1 (en) 2006-11-22
ATE346063T1 (de) 2006-12-15
NO20034715L (no) 2003-12-10
RU2003133213A (ru) 2005-05-10
UA77671C2 (en) 2007-01-15
SI1390360T1 (sl) 2007-04-30
JP4455815B2 (ja) 2010-04-21
US7553856B2 (en) 2009-06-30
NZ528917A (en) 2006-02-24
EP1390360A1 (en) 2004-02-25
HRP20030853A2 (en) 2005-08-31
PL366471A1 (en) 2005-02-07
MXPA03009789A (es) 2005-03-07
US20040122056A1 (en) 2004-06-24
CA2445251A1 (en) 2002-10-31
DE60216273T2 (de) 2007-05-31
HRP20030853B1 (en) 2011-11-30
CN1531533B (zh) 2012-07-18
JP2004526786A (ja) 2004-09-02
BG108287A (bg) 2005-04-30
RS50880B (sr) 2010-08-31
CN1531533A (zh) 2004-09-22
NO20034715D0 (no) 2003-10-21
US20060079560A1 (en) 2006-04-13
CZ20032911A3 (en) 2004-06-16
RU2286991C2 (ru) 2006-11-10
WO2002085889A1 (en) 2002-10-31
DE60216273D1 (de) 2007-01-04
AU2002307892B2 (en) 2008-04-17
IL158561A0 (en) 2004-05-12
HUP0303928A2 (hu) 2004-03-01
KR20030094358A (ko) 2003-12-11
ZA200307988B (en) 2004-10-14
SK13192003A3 (sk) 2004-03-02
BR0209103A (pt) 2004-07-13
CA2445251C (en) 2011-01-04

Similar Documents

Publication Publication Date Title
US7553856B2 (en) Crystalline form of omeprazole
KR101880255B1 (ko) 리팍시민 및 아미노산을 포함하는 약학적 조성물, 이의 제조방법 및 용도
KR20130016225A (ko) 디아민 유도체의 결정 및 그 제조 방법
PL190870B1 (pl) Nowa krystaliczna postać omeprazolu
AU2002307892A1 (en) Crystalline form of omeprazole
CA3235361A1 (en) Polymorphs of the hydrochloride salt of linaprazan glurate
CN115385845B (zh) 一种吡咯磺酸类化合物盐型制备
BR112019010934A2 (pt) composições e métodos relacionados a agonistas de piridinoilpiperidina 5-ht1f
JPH01261388A (ja) 置換キノリン誘導体
CA2225022C (en) New polymorphous form of doxazosine mesylate (form iii)
CN114685434B (zh) 一种阿昔替尼与戊二酸共晶
RO122491B1 (ro) Derivaţi de benzimidazol, alcoxi substituiţi, compoziţii farmaceutice care îi conţin şi utilizarea acestora
CN114685438B (zh) 一种阿昔替尼苹果酸新盐
CN114685466B (zh) 一种阿昔替尼共晶盐
RU2663617C1 (ru) Новая кристаллическая форма метансульфонат 5-хлор-n-({ (5s)-2-оксо-3-[4-(5,6-дигидро-4h-[1,2,4]триазин-1-ил)фенил]-1,3-оксазолидин-5-ил} метил)тиофен-2-карбоксамида и содержащая его фармацевтическая композиция
CN114685431B (zh) 一种阿昔替尼柠檬酸盐晶型
CN114685435B (zh) 阿昔替尼马来酸盐晶型及其制备
CN112451520B (zh) 一种缬沙坦氨氯地平组合物及其制备方法
CN114685432A (zh) 阿昔替尼盐晶型及其制备方法
CN114685437A (zh) 阿昔替尼与糖精共晶

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20110511